Thursday, December 09, 2021
Filament Health (FLHLF)
Initiating Coverage With An Outperform Rating
Filament Health Corp is a natural psychedelic drug discovery and extraction technology company. Its mission is to see safe, approved, natural psychedelics in the hands of everyone who needs them as soon as possible. Filament engages in natural extraction technology commercialization, utilizing its intellectual property portfolio, in-house GMP facility, and Health Canada psilocybin Dealer’s License.
Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Filament Health Is Developing Natural Psychedelic Botanical Drugs For Psychiatric Conditions. Filament Health has developed proprietary methods for producing naturally occurring psilocybin, psilocin, and other psychoactive compounds from plants and fungi. These compounds have been formulated for use in treating psychiatric conditions and mental health. It has three products that have received FDA approval to begin clinical testing in 1Q22.
Focus On Natural Molecules. Filament Health is developing products based on the natural composition of molecules found in plants and fungi. These are purified formulations of natural compounds that have established use in modern society and indigenous cultures. The company has a patent estate covering the methods of extraction and purification through to the administration of the final …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
